“A great strategic mind”
“Remarkable grasp of issues”

Chambers USA 2020

Joshua M. Dubofsky

Silicon Valley | New York
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA
 
 

Josh Dubofsky advises market-leading companies and private equity firms on strategic transactions and corporate governance matters.

Mr. Dubofsky has nearly 20 years of experience advising corporate clients and private equity firms in their most complex domestic and cross-border transactions. He regularly advises on significant public company transactions and governance matters, private company mergers and acquisitions, and private equity investments.

Mr. Dubofsky works closely with boards of directors, management, and shareholders on:

  • Mergers, acquisitions, and other strategic corporate transactions
  • Public and private equity and debt financing
  • Corporate governance, takeover planning, and activism defense
  • General corporate representation of both publicly traded and privately held companies

Mr. Dubofsky has a demonstrated ability to navigate complex transactions across a range of industries, including:

  • Life sciences
  • Internet and digital media
  • Information technology
  • Retail and consumer products
  • Transportation
  • Financial services

Mr. Dubofsky’s representative experience includes:

Healthcare and Life Sciences
  • Siemens Healthineers in a pending US$16.4 billion acquisition of Varian Medical Systems
  • GenesisCare in an acquisition of 21st Century Oncology
  • Relypsa in a US$1.5 billion sale to Galenica AG
  • Kythera Biopharmaceuticals in a US$2.1 billion sale to Allergan plc
  • Menlo Therapeutics in a merger with Foamix Pharmaceuticals
  • Encore Vision in a US$465 million acquisition by Novartis AG
  • Allergan in the US$40.5 billion sale of its Actavis Generics business to Teva
  • ArthroCare Corporation in a US$1.7 billion sale to Smith & Nephew
  • Conceptus in a US$1.1 billion sale to Bayer AG
  • Medicis Pharmaceuticals in its acquisition by Valeant Pharmaceuticals for US$2.6 billion
  • ZymoGenetics in a US$885 million acquisition by Bristol-Meyers Squibb
  • A special committee of the board of directors of Genentech in the US$47 billion acquisition of the outstanding publicly held stock of Genentech by Roche
Technology
  • NVIDIA in a pending US$40 billion acquisition of Arm  
  • Opendoor in a pending US$4.8 billion merger with Social Capital Hedosophia II 
  • Cradlepoint in a pending US$1.1 billion sale to Ericsson   
  • Mellanox Technologies in:
    • US$6.9 billion sale to NVIDIA
    • Acquisition of Cumulus Networks
    • Proxy contest defense against Starboard Value
  • Integrated Device Technology in its:    
    • US$6.7 billion sale to Renesas Electronics
    • US$250 million acquisition of GigPeak
  • DXC Technology in a US$2 billion acquisition of Luxoft Holding

  • The independent directors of Rackspace Hosting in Rackspace’s US$4.3 billion acquisition by Apollo Global Management
  • A special committee of the board of directors of Google in the class C non-voting common stock recapitalization of Google
  • ChaSerg Technology Acquisition Corp. in a US$515 million merger with Grid Dynamics
  • Netsmart, a Genstar Capital portfolio company, in a US$950 million sale to GI Partners and Allscripts
  • Adobe Systems in a US$1.8 billion acquisition of Omniture
Transportation, Communications, Retail, and Real Estate
  • T-Mobile US in its:
    • US$26 billion merger with Sprint
    • US$5 billion divestiture of Sprint’s prepaid businesses to DISH
  • US Airways in a US$17 billion merger with American Airlines
  • Virgin Galactic in its US$1.5 billion merger with Social Capital Hedosophia
  • American Airlines in a US$200 million investment in China Southern Airlines
  • Troon Golf in a sale to Kohlberg & Company and Great White Shark Enterprises
  • Skechers USA in connection with the 3:1 split of its Class A and Class B common stock
  • Guitar Center in a sale to Bain Capital for US$1.9 billion
Private Equity and Venture Capital

Representative clients have included Technology Crossover Ventures, Spectrum Equity, KKR, Genstar Capital, One Equity Partners, The Carlyle Group, and Weston Presidio, and recent matters include:

  • KKR in its investments in Ajax Health, Blue Sprig Pediatrics, BridgeBio Pharma, Ebb Sleep, Falcon Vision, Impel Neuropharma, Signostics, Spirox, and Slayback Pharma
  • Technology Crossover Ventures in public and private investments and divestitures of portfolio companies, including investments in Alarm.com, Netflix, theStreet.com, and MarketAxess and the sales of ExactTarget, Fiberlink, FX Alliance, iPipeline, and XRS Corporation
  • Spectrum Equity in acquisitions of ExactBid and PicMonkey
  • Centerbridge Partners in its sale of Cardinal Logistics
  • One Equity Partners in its Media Solutions partnership with Ericsson
  • Indigo Partners in the acquisition of Frontier Airlines from Republic Airways
  • Weston Presidio in the sale of its investments in Apple American Group, Star Manufacturing, and The Wolf Organization
Activism Defense
  • Cars.com in its engagement with Starboard Value
  • Cerner in its cooperation agreement with Starboard Value
  • e.l.f. Beauty in its cooperation agreement with Marathon Partners
  • Innovative Food Holdings, Inc, in its agreement with JCP Investment Management
  • Mellanox in its settlement agreement with Starboard Value
  • Nevro in its settlement agreement with Broadfin Capital
Financial Advisor Representation

Mr. Dubofsky also represents financial advisors in public and private strategic transactions, including, among others:

  • JPMorgan in the:
    • Pending US$68 billion merger of Analog Devices and Maxim Integrated Products
    • Acquisition by Cisco of ThousandEyes
    • Acquisition by Salesforce of Salesforce.org
  • Credit Suisse in the:
    • US$1.4 billion acquisition by New Media of Gannett
    • Reclassification by Comcast of its Class A common stock
  • Morgan Stanley in the US$2.1 billion acquisition of Carbon Black by VMWare
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.